This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Quadrivalent Seasonal Flu Vaccine
Drug Names(s): VLP influenza vaccine (NVAX)
Description: Novavax is producing virus-like particles VLPs to develop vaccines for both seasonal and pandemic strains of influenza. They produce VLPs using a baculovirus expression system in insect cells. VLPs are self-assembling protein structures that resemble viruses. These are non-infectious particles that for many viral diseases have been shown in animal and human studies to make effective vaccines. VLPs closely mimic natural virus particles with repeating protein structures that can elicit broad and strong antibody and cellular immune responses, but lack the genetic material required for replication.
Deal Structure: In February 2011, LG Life Sciences (LGLS) entered into a licensing agreement with Novavax to manufacture, develop and commercialize influenza vaccines using Novavaxs VLP technology in South Korea and other countries. Novavax will receive upfront and milestone payments from LGLS in addition to double-digit royalty rate payments from commercial sales. Novavax will provide VLP technology transfer and manufacturing support for LGLSs new vaccine production facility.
Partners: LG Life Sciences Ltd.
Quadrivalent Seasonal Flu Vaccine News
Additional information available to subscribers only: